Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. Issue 12 (18th June 2018)

• Record Type: Journal Article
• Authors: Ribback, Silvia; Che, Li; Pilo, Maria G.; Cigliano, Antonio; Latte, Gavinella; Pes, Giovanni M.; Porcu, Alberto; Pascale, Rosa M.; Li, Lei; Qiao, Yu; Dombrowski, Frank; Chen, Xin; Calvisi, Diego F.
• Is Part Of: Cell cycle. Volume 17:Issue 12(2018)
• Page Start: 1496
• Page End: 1512
• Publication Date: 2018-06-18
• Subjects: Liver cancer -- tumor metabolism -- lipogenesis -- mouse models; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2018.1489182
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Metabolic reprogramming is a hallmark of many cancer types, including hepatocellular carcinoma (HCC). Identifying the critical players in this process might be crucial for the generation of novel and effective anti-neoplastic therapies. In the present investigation, we determined the importance of carbohydrate responsive element binding protein (ChREBP), a central player in the regulation of lipid and glucose metabolism in the liver, on the development of HCC in in vitro and in vivo models. We found that genetic deletion of ChREBP (that will be referred to as ChREBPKO mice) strongly delays or impairs hepatocarcinogenesis driven by AKT or AKT/c-Met overexpression in mice, respectively. In contrast, HCC development was found to be completely unaffected by ChREBP depletion in mice co-expressing AKT and N-Ras protooncogenes. In mouse and human HCC cell lines, suppression of ChREBP via specific small interfering RNAs (siRNAs) resulted in decreased proliferation and induction of apoptosis. Of note, these cellular events were strongly augmented by concomitant inhibition of the mitogen-activated protein kinase (MAPK) pathway. The present data indicate that ChREBP activity might be required or dispensable for HCC growth, depending on the oncogenes involved. In particular, the activation of Ras/MAPK signaling might represent a possible mechanism of resistance to ChREBP depletion in this tumor type. Additional studies are needed to unravel the molecular mechanisms rendering HCC cells insensitive to ChREBP suppression.